Stapokibart
As of the edition of 20 October 2026, Stapokibart is an antibody: in active development; acts on IL4R.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2027
- Kind
- Antibody
- Registered trials
- 38, 0 stopped early
- Disease areas
- Immune system; Skin and connective tissue; Inherited and neonatal; Lungs and airways; Ear, nose and throat; Blood and lymph
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IL4R | Interleukin-4 receptor subunit alpha | P24394 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 7 | 0 | 6 | 0 |
| Phase 1 | 3 | 2 | 0 | 0 |
| Phase 2 | 16 | 11 | 2 | 0 |
| Phase 3 | 11 | 4 | 7 | 0 |
| Phase 4 | 1 | 0 | 1 | 0 |
| All trials | 38 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Keymed Biosciences Co.Ltd | Lead sponsor of trials | 2019 to now |
| Cspc | Lead sponsor of trials | 2023 to now |
| Chengdu Kangnuoxing Biopharma | Lead sponsor of trials | 2025 to now |